13F filer · CIK 1652044 ↗

Alphabet Inc.

You are looking at Q2 2022. See the latest, Q2 2026 →

Reported value

$1.84B

−40% on the quarter before

Positions

2 new · 7 sold out

Top 10

78.7%

of the value

Est. gain

−$913.8M

on stocks held all quarter

Est. return

−33.6%

on those stocks since Q1 2022

Filed

Nov 15, 2022

On SEC EDGAR ↗

Positions as of Jun 30, 2022, from Alphabet Inc.'s 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.

Portfolio at a glance

New
Added
Cut
Same
Options

Each tile is a position, sized by its share, colored by what the fund did with it since Q1 2022. Striped tiles are options.

Dexcom Inc17%

UiPath14%

Eqrx Inc12%

Verve Therapeutics Inc9.1%

Planet Labs Pbc7.5%

Oscar Health Inc5.5%

31 others5.4%

Lyft Inc4.4%

Snowflake4.0%

Freshworks Inc2.9%

Benson Hill Inc2.3%

Robinhood2.2%

Lyell Immunopharma Inc2.1%

Gitlab Inc1.7%

Relay Therapeutics Inc1.4%

Desktop Metal Inc1.3%

Adagio Therapeutics Inc1.0%

Toast1.0%

Sana Biotechnology Inc1.0%

23andme Holding Co0.9%

0.8%

0.7%

0.6%

0.5%

Dexcom Inc17%

UiPath14%

Eqrx Inc12%

Verve Therapeutics Inc9.1%

Planet Labs Pbc7.5%

Oscar Health Inc5.5%

31 others5.4%

Lyft Inc4.4%

Snowflake4.0%

Freshworks Inc2.9%

Benson Hill Inc2.3%

Robinhood2.2%

Lyell Immunopharma Inc2.1%

Gitlab Inc1.7%

Relay Therapeutics Inc1.4%

Desktop Metal Inc1.3%

Adagio Therapeutics Inc1.0%

Toast1.0%

Sana Biotechnology Inc1.0%

23andme Holding Co0.9%

0.8%

0.7%

0.6%

0.5%

Largest buys

Since Q1 2022, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.

Gitlab Inc~$31.5MNew · 0.0% → 1.7%+593,404 shares
Velo3d Inc~$7.4MNew · 0.0% → 0.4%+5,361,671 shares

Largest sells

Since Q1 2022, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.

IonQ~$279.5MSold out · 9.1% → 0.0%−21,907,038 shares
Arcus Biosciences Inc~$80.9MSold out · 2.6% → 0.0%−2,563,441 shares
Dexcom Inc~$1.1MCut · 17.4% → 16.9%−14,226 shares
Twilio~$611,000Sold out · 0.0% → 0.0%−3,710 shares
Nextdoor Holdings Inc~$583,000Sold out · 0.0% → 0.0%−97,391 shares
Sqz Biotechnologies Co~$500,000Sold out · 0.0% → 0.0%−103,929 shares
Compass Therapeutics Inc~$264,000Sold out · 0.0% → 0.0%−192,794 shares
S&P Global Inc~$243,000Sold out · 0.0% → 0.0%−592 shares
Science 37 Holdings Inc~$67,972Cut · 0.6% → 0.3%−33,815 shares

Holdings

As of Jun 30, 2022. Changes are in shares against Mar 31, 2022, so a price move alone never reads as a buy or a sale.

Positions, sorted by share of the portfolio
#	Holding		% prev	Value	Shares		Price	Prev price
1	Dexcom IncCOM · shares −0.3% · price −41.7%	16.9%	17.4%	$312.1M	4.2M	−0.3%	$74.53	$127.904:1 split	−41.7%	−$223.5M
2	UiPathCL A · shares 0% · price −15.7%	13.9%	9.9%	$255.9M	14.1M	0%	$18.19	$21.59	−15.7%	−$47.8M
3	Eqrx IncCOM · shares 0% · price +13.6%	12.1%	6.4%	$223.0M	47.6M	0%	$4.69	$4.13	+13.6%	+$26.6M
4	Verve Therapeutics IncCOM · shares 0% · price −33.0%	9.1%	8.1%	$167.7M	11.0M	0%	$15.28	$22.82	−33.0%	−$82.7M
5	Planet Labs PbcCOM CL A · shares 0% · price −14.8%	7.5%	5.3%	$138.3M	31.9M	0%	$4.33	$5.08	−14.8%	−$24.0M
6	Oscar Health IncCL A · shares 0% · price −57.4%	5.5%	7.8%	$102.2M	24.0M	0%	$4.25	$9.97	−57.4%	−$137.5M
7	Lyft IncCL A COM · shares 0% · price −65.4%	4.4%	7.6%	$81.5M	6.1M	0%	$13.28	$38.40	−65.4%	−$154.2M
8	SnowflakeCL A · shares 0% · price −39.3%	4.0%	4.0%	$74.5M	535,604	0%	$139.06	$229.13	−39.3%	−$48.2M
9	Freshworks IncCLASS A COM · shares 0% · price −26.6%	2.9%	2.3%	$53.1M	4.0M	0%	$13.15	$17.92	−26.6%	−$19.2M
10	Benson Hill IncCOMMON STOCK · shares 0% · price −15.2%	2.3%	1.6%	$42.1M	15.4M	0%	$2.74	$3.23	−15.2%	−$7.5M
11	RobinhoodCOM CL A · shares 0% · price −39.2%	2.2%	2.2%	$40.5M	4.9M	0%	$8.22	$13.51	−39.2%	−$26.1M
12	Lyell Immunopharma IncCOM · shares 0% · price +29.1%	2.1%	0.96%	$38.2M	5.9M	0%	$6.52	$5.05	+29.1%	+$8.6M
13	Gitlab IncCLASS A COM · shares New	1.7%	—	$31.5M	593,404	New	$53.14	—	—	—
14	Relay Therapeutics IncCOM · shares 0% · price −44.0%	1.4%	1.5%	$26.3M	1.6M	0%	$16.75	$29.93	−44.0%	−$20.7M
15	Desktop Metal IncCOM CL A · shares 0% · price −53.6%	1.3%	1.7%	$24.3M	11.0M	0%	$2.20	$4.74	−53.6%	−$28.1M
16	Adagio Therapeutics IncCOM · shares 0% · price −28.1%	1.0%	0.84%	$18.6M	5.7M	0%	$3.28	$4.56	−28.1%	−$7.3M
17	ToastCL A · shares 0% · price −40.5%	1.0%	1.0%	$18.5M	1.4M	0%	$12.94	$21.73	−40.5%	−$12.6M
18	Sana Biotechnology IncCOM · shares 0% · price −22.2%	0.98%	0.75%	$18.1M	2.8M	0%	$6.43	$8.26	−22.2%	−$5.1M
19	23andme Holding CoCLASS A COM · shares 0% · price −35.2%	0.91%	0.84%	$16.7M	6.7M	0%	$2.48	$3.83	−35.2%	−$9.1M
20	Monte Rosa Therapeutics IncCOM · shares 0% · price −31.0%	0.77%	0.67%	$14.2M	1.5M	0%	$9.67	$14.02	−31.0%	−$6.4M
21	Duolingo Inc.CL A COM · shares 0% · price −7.9%	0.69%	0.45%	$12.6M	144,444	0%	$87.55	$95.11	−7.9%	−$1.1M
22	Beam Therapeutics IncCOM · shares 0% · price −32.4%	0.68%	0.60%	$12.4M	321,604	0%	$38.71	$57.30	−32.4%	−$6.0M
23	Ideaya Biosciences IncCOM · shares 0% · price +23.3%	0.56%	0.27%	$10.4M	753,187	0%	$13.80	$11.19	+23.3%	+$2.0M
24	Rapt Therapeutics IncCOM · shares 0% · price −17.0%	0.54%	0.39%	$9.9M	540,270	0%	$18.25	$21.99	−17.0%	−$2.0M
25	Illumina IncCOM · shares 0% · price −47.2%	0.54%	0.61%	$9.9M	53,470	0%	$184.37	$349.39	−47.2%	−$8.8M
	Total · 55 positions	100%		$1.84B						−$913.8M

The filing on SEC EDGAR ↗

Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.

What made money

From Q1 2022 to Q2 2022: 53 stocks held throughout, down $913.8M (−33.6%).

Eqrx Inc+$26.6M+14%
Lyell Immunopharma Inc+$8.6M+29%
Ideaya Biosciences Inc+$2.0M+23%
Decibel Therapeutics Inc+$1.9M+39%
Tscan Therapeutics Inc+$371,000+12%
Snowflake−$48.2M−39%
Verve Therapeutics Inc−$82.7M−33%
Oscar Health Inc−$137.5M−57%
Lyft Inc−$154.2M−65%
Dexcom Inc4:1 split−$223.5M−42%

Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out, 1 split read into the share counts.

Reported value by quarter

The total value of each quarter's 13F at that quarter end. It moves with prices as well as with buying and selling. Pick a quarter to see what the fund held then.

$110.00B$55.00B$0

Q1 201642 quartersQ2 2026

Every quarter's filing

Each quarter's 13F filing, newest first
Quarter	Filed	Reported value	Positions	Filing
Q2 2026	Aug 7, 2026	$99.08B+2,367%	28	SEC ↗
Q1 2026	May 8, 2026	$4.02B+56%	26	SEC ↗
Q4 2025	Feb 13, 2026	$2.58B+7%	29	SEC ↗
Q3 2025	Nov 7, 2025	$2.41B+13%	37	SEC ↗
Q2 2025	Aug 1, 2025	$2.14B+35%	36	SEC ↗
Q1 2025	May 2, 2025	$1.58B−8%	40	SEC ↗
Q4 2024	Feb 7, 2025	$1.72B−7%	40	SEC ↗
Q3 2024	Nov 8, 2024	$1.84B−7%	42	SEC ↗
Q2 2024	Aug 2, 2024	$1.97B−21%	42	SEC ↗
Q1 2024	May 3, 2024	$2.51B+17%	43	SEC ↗
Q4 2023	Feb 9, 2024	$2.16B+39%	44	SEC ↗
Q3 2023	Nov 13, 2023	$1.56B−16%	45	SEC ↗
Q2 2023	Aug 4, 2023	$1.86B+3%	47	SEC ↗
Q1 2023	May 11, 2023	$1.80B+5%	49	SEC ↗
Q4 2022	Feb 14, 2023	$1.72B−12%	51	SEC ↗
Q3 2022	Nov 15, 2022	$1.96B+6%	49	SEC ↗
Q2 2022	Nov 15, 2022	$1.84B−40%	55	SEC ↗
Q1 2022	Nov 15, 2022	$3.08B−26%	60	SEC ↗
Q4 2021	Nov 15, 2022	$4.14B−2%	58	SEC ↗
Q3 2021	Nov 15, 2022	$4.22B−14%	43	SEC ↗
Q2 2021	Nov 15, 2022	$4.91B+98%	36	SEC ↗
Q1 2021	Nov 15, 2022	$2.48B+19%	32	SEC ↗
Q4 2020	Nov 15, 2022	$2.08B−2%	31	SEC ↗
Q3 2020	Nov 15, 2022	$2.13B−2%	24	SEC ↗
Q2 2020	Nov 15, 2022	$2.17B+42%	24	SEC ↗
Q1 2020	Nov 15, 2022	$1.52B−8%	25	SEC ↗
Q4 2019	Nov 15, 2022	$1.65B−50%	24	SEC ↗
Q3 2019	Nov 15, 2022	$3.33B−37%	24	SEC ↗
Q2 2019	Nov 15, 2022	$5.27B+172%	22	SEC ↗
Q1 2019	Nov 15, 2022	$1.94B+129%	17	SEC ↗
Q4 2018	Nov 15, 2022	$845.8M−19%	17	SEC ↗
Q3 2018	Nov 15, 2022	$1.04B−12%	17	SEC ↗
Q2 2018	Nov 15, 2022	$1.19B+94%	17	SEC ↗
Q1 2018	Nov 15, 2022	$614.8M+67%	11	SEC ↗
Q4 2017	Nov 15, 2022	$368.6M+7%	8	SEC ↗
Q3 2017	Nov 15, 2022	$344.0M−1%	4	SEC ↗
Q2 2017	Nov 15, 2022	$347.4M+10%	4	SEC ↗
Q1 2017	Nov 15, 2022	$316.8M+8%	3	SEC ↗
Q4 2016	Nov 15, 2022	$292.8M+6%	2	SEC ↗
Q3 2016	Nov 15, 2022	$275.2M+31%	2	SEC ↗
Q2 2016	Nov 15, 2022	$209.8M−14%	3	SEC ↗
Q1 2016	Nov 15, 2022	$242.9M	5	SEC ↗